Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephen Quarterman

Physician Assistant Anderson, SC Physician Assistant

NPI 1427100254 CMS profile 11127325

2503 North Main Street, Anderson Skin & Cancer Clinic PA, Anderson, SC 29621

Open in the dashboard

General payments

$5,594

259 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Quarterman of Anderson, SC is reported in the CMS Open Payments database as having received $5,594 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,151 58
2024 General $1,569 69
2023 General $1,661 74
2022 General $883 45
2021 General $331 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Quarterman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stephen Quarterman were reported at $1,151. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stephen Quarterman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $331 $132 $37–$438 $132
2022 $883 $155 $48–$522 $149
2023 $1,661 $167 $52–$557 $160
2024 $1,569 $178 $55–$600 $164
2025 $1,151 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,001 46 payments
  2. Regeneron Healthcare Solutions, Inc. $852 36 payments
  3. AbbVie, Inc. $757 42 payments
  4. Sun Pharmaceutical Industries Inc. $553 28 payments
  5. Incyte Corporation $421 12 payments
  6. UCB, Inc. $278 16 payments
  7. Amgen Inc. $261 8 payments
  8. Novartis Pharmaceuticals Corporation $174 8 payments
  9. LEO Pharma Inc. $145 7 payments
  10. Pfizer Inc. $144 8 payments
  11. Other $1,009 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,130 252 payments
  2. Education $464 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $920 39 payments
  2. DUPIXENT Inflammation And Immunology $592 24 payments
  3. ILUMYA $493 27 payments
  4. RINVOQ $483 24 payments
  5. OPZELURA $421 12 payments
  6. Otezla $261 8 payments
  7. SKYRIZI $218 15 payments
  8. DUPIXENT Immunology And Inflammation $214 10 payments
  9. Bimzelx $213 13 payments
  10. SIMPONI ARIA $149 11 payments
  11. Other $2,555 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

690

Median for Physician Assistant: 241

Drug cost

$84,003

Median for Physician Assistant: $4,110

Branded share of claims

15.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 12 $64,782
Desonide Generic 29 $2,560
Betamethasone Dipropionate Generic 76 $2,296
Clobetasol Propionate Generic 56 $2,049
Triamcinolone Acetonide Generic 145 $2,008
Desoximetasone Generic 20 $1,622
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 67 $1,329
Metronidazole Generic 13 $1,025
Fluorouracil Generic 15 $1,002
Clindamycin Phosphate Generic 26 $965

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$51,515

Medicare's payments for the services billed

Medicare patients

441

Average age 74

Services billed

1,353

197 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Ischemic heart disease 27%
Diabetes 22%
Chronic kidney disease 20%
Atrial fibrillation 17%
Depression 17%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $251
  • GENZYME CORPORATION $60
$312 12 —
TREMFYA
  • Janssen Biotech, Inc. $223
$223 — —
RINVOQ
  • AbbVie, Inc. $218
$218 — —
OPZELURA
  • Incyte Corporation $103
$103 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record